Blessed with its first-ever FDA approval, little-known Kadmon is revving up the commercial engine to debut its new graft-versus-host disease drug by summer’s end. Kadmon plans to launch Rezurock, also ...

Looking to bolster Sanofi's portfolio of marketed drugs and pipeline prospects, CEO Paul Hudson went on a dealmaking spree last year. That included the drugmaker's $1.9 billion buyout of Kadmon, where ...

"The availability of REZUROCK is a turning point for patients living with cGVHD as they seek new safe and effective treatment options for this debilitating disease," said Harlan W. Waksal, M.D., ...

Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two ...

According to financial terms announced Wednesday, Sanofi will pay $9.50 for each share of Kadmon, a premium of 79% over the company’s $5.30 closing stock price on Tuesday, and about 113% more than the ...

Kadmon, the biotechnology company founded by ImClone's Sam Waksal, is preparing to file confidentially for an initial public offering, according to people familiar with the matter. The S-1 document is ...

NEW YORK, NY / ACCESSWIRE / February 11, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced the pricing of $200 million aggregate principal amount of 3.625% convertible senior notes due 2027 ...

Kadmon badly needs a new product to sell because its only source of revenue at the moment is ribavirin, an obsolete antiviral formerly used to treat the hepatitis C virus. Investors breathed a sigh of ...

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)-- Dyax Corp. (NAS: DYAX) and Kadmon Corporation, LLC (Kadmon) announced today that they have entered into a strategic licensing agreement in which Kadmon ...